Methods for treating disorders associated with mGLU receptors including addiction and depression

Abstract

Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGluRs belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with mGlu receptors 2, 3, and 5, including administering to a subject in need thereof an effective amount of at least one antagonist which modulates mGluR2, mGluR3, and mGluR5. The disorders treated by the method include, for example, nicotine addiction, cocaine addiction, and depression.

1 - 9 . (canceled) 
     
     
         10 . A combination comprising (a) a first antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3, and (b) a second antagonist which modulates metabotropic glutamate receptor 5 in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use. 
     
     
         11 . A combination comprising (a) at least one active ingredient which exhibits antagonistic activity against the metabotropic glutamate receptor 2 and the metabotropic glutamate receptor 3, and (b) at least one metabotropic glutamate receptor 5 antagonist, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use. 
     
     
         12 - 13 . (canceled) 
     
     
         14 . The combination according to  claim 10  which is a combined preparation or a pharmaceutical composition. 
     
     
         15 . The combination according to  claim 10  for simultaneous, separate or sequential use in the treatment of an addictive disorder or depression. 
     
     
         16 . (canceled) 
     
     
         17 . A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against an addictive disorder or depression, of the combination according to  claim 10  and at least one pharmaceutically acceptable carrier. 
     
     
         18 . (canceled) 
     
     
         19 . A commercial package comprising a combination according to  claim 10  together with instructions for simultaneous, separate or sequential use thereof in the treatment of an addictive disorder or depression. 
     
     
         20 - 31 . (canceled) 
     
     
         32 . The combination according to  claim 10 , wherein the antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid, and the antagonist which modulates metabotropic glutamate receptor 5 is 2-methyl-6-(phenylethynyl)-pyridine. 
     
     
         33 . The combination of  claim 15 , wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction. 
     
     
         34 . The commercial package of  claim 19 , wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.